CIK 0001710072 · Large accelerated filer
Edgewise Therapeutics, Inc.
Sign in to watch- Ticker
- EWTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821725586
- Phone
- 720-262-7002
- Business address
- 1715 38TH ST, BOULDER, CO, 80301
- DEFA14A Proxy Proxy Materials
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale Chief Scientific Officer sold 1,551 shares at $16.45 ($25,520)
- 4 Open-market sale General Counsel sold 1,930 shares at $16.45 ($31,757)
- 4 Open-market sale President and CEO sold 4,276 shares at $16.45 ($70,358)
- 4 Open-market sale CMO sold 5,187 shares at $16.45 ($85,348)
- 4 Open-market sale Chief Business Officer sold 1,691 shares at $16.45 ($27,824)
- 4 Open-market sale Chief Financial Officer sold 1,314 shares at $16.45 ($21,621)
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Open-market buy Director bought 496,771 shares at $20.13 ($10,000,000)
- 4 Open-market buy Director bought 496,771 shares at $20.13 ($10,000,000)
- 4 Grant or award Director acquired 559 shares (grant or award)
- 424B5 Offering Prospectus
- 8-K Event Material agreement · Regulation FD disclosure
- 8-K Event Regulation FD disclosure · Other events
- 4 Planned sale Chief Scientific Officer sold 200 shares at $30.02 ($6,004)
Page 6 of 22 · 423 filings